Literature DB >> 26407785

The responsiveness of the different versions of the Hamilton Depression Scale.

Per Bech1.   

Abstract

Entities:  

Year:  2015        PMID： 26407785      PMCID： PMC4592652          DOI： 10.1002/wps.20248

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  9 in total

1.  Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?

Authors:  Arif Khan; Amritha Bhat; Russell Kolts; Michael E Thase; Walter Brown
Journal:  CNS Neurosci Ther       Date:  2010-04-16       Impact factor: 5.243

Review 2.  Report by the ACNP Task Force on response and remission in major depressive disorder.

Authors:  A John Rush; Helena C Kraemer; Harold A Sackeim; Maurizio Fava; Madhukar H Trivedi; Ellen Frank; Philip T Ninan; Michael E Thase; Alan J Gelenberg; David J Kupfer; Darrel A Regier; Jerrold F Rosenbaum; Oakley Ray; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

3.  HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

Authors:  P Bech; P Boyer; J-M Germain; K Padmanabhan; V Haudiquet; B Pitrosky; K A Tourian
Journal:  Pharmacopsychiatry       Date:  2010-09-09       Impact factor: 5.788

4.  Fewer study participants needed to demonstrate superior antidepressant efficacy when using the Hamilton melancholia subscale (HAM-D₆) as outcome measure.

Authors:  Søren Dinesen Østergaard; Per Bech; Kamilla Woznica Miskowiak
Journal:  J Affect Disord       Date:  2014-11-07       Impact factor: 4.839

5.  Is the antidepressive effect of second-generation antidepressants a myth?

Authors:  P Bech
Journal:  Psychol Med       Date:  2010-02       Impact factor: 7.723

6.  Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.

Authors:  L F Fabre; F S Abuzzahab; M Amin; J L Claghorn; J Mendels; W M Petrie; S Dubé; J G Small
Journal:  Biol Psychiatry       Date:  1995-11-01       Impact factor: 13.382

7.  Antidepressants versus placebo in major depression: an overview.

Authors:  Arif Khan; Walter A Brown
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

8.  Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Authors:  Michael R Liebowitz; Amy L Manley; Sudharshan K Padmanabhan; Rita Ganguly; Raj Tummala; Karen A Tourian
Journal:  Curr Med Res Opin       Date:  2008-05-27       Impact factor: 2.580

9.  Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).

Authors:  Søren D Ostergaard; Per Bech; Madhukar H Trivedi; Stephen R Wisniewski; A John Rush; Maurizio Fava
Journal:  J Affect Disord       Date:  2014-04-03       Impact factor: 4.839
  9 in total
  12 in total

1.  The clinical relevance of qualitatively distinct subtypes of depression.

Authors:  Lars Vedel Kessing; Jens Drachmann Bukh
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

2.  Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.

Authors:  Cong Yao; Lichao Niu; Yun Fu; Xu Zhu; Junfeng Yang; Peng Zhao; Xiaoxiao Sun; Yanyan Ma; Shen Li; Jie Li
Journal:  J Neural Transm (Vienna)       Date:  2021-11-27       Impact factor: 3.850

3.  Depressive Symptom Dimensions in Treatment-Resistant Major Depression and Their Modulation With Electroconvulsive Therapy.

Authors:  Benjamin S C Wade; Gerhard Hellemann; Randall T Espinoza; Roger P Woods; Shantanu H Joshi; Ronny Redlich; Anders Jørgensen; Christopher C Abbott; Ketil J Oedegaard; Shawn M McClintock; Leif Oltedal; Katherine L Narr
Journal:  J ECT       Date:  2020-06       Impact factor: 3.692

4.  MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as predictors of response to antidepressant treatment.

Authors:  Wei-Hong Kuang; Zai-Quan Dong; Lian-Tian Tian; Jin Li
Journal:  Braz J Med Biol Res       Date:  2018-05-17       Impact factor: 2.590

5.  Clinical characteristics of moderate-severe obsessive-compulsive disorder in children and adolescents in China.

Authors:  Liyuan Luo; Bin Feng; Senjun Yang; Ning Zhang; Shengliang Qiu
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

6.  Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials.

Authors:  Michael P Hengartner; Janus C Jakobsen; Anders Sørensen; Martin Plöderl
Journal:  PLoS One       Date:  2020-02-26       Impact factor: 3.240

7.  The challenge of measurement in psychiatry: the lifetime accomplishments of Per Bech (1942-2018).

Authors:  Marcelo P Fleck; Danilo Carrozzino; Giovanni A Fava
Journal:  Braz J Psychiatry       Date:  2019-10-17       Impact factor: 2.697

8.  Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Yi-Fan Li; Hui-Min Hu; Bo-Ning Wang; Yi Zhang; Xing Liu; Peng Mao; Bi-Fa Fan
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-22       Impact factor: 2.629

9.  Transcranial pulsed electromagnetic fields for treatment-resistant depression: A multicenter 8-week single-arm cohort study.

Authors:  Erik Roj Larsen; Rasmus W Licht; René Ernst Nielsen; Annette Lolk; Bille Borck; Claus Sørensen; Ellen Margrethe Christensen; Gustav Bizik; Janus Ravn; Klaus Martiny; Maj Vinberg; Odeta Jankuviené; Pernille Blenker Jørgensen; Poul Videbech; Per Bech
Journal:  Eur Psychiatry       Date:  2020-02-18       Impact factor: 5.361

10.  Demographic Factors and Cognitive Function Assessments Associated with Mild Cognitive Impairment Progression for the Elderly.

Authors:  Hong-Yun Qin; Xu-Dong Zhao; Bing-Gen Zhu; Cheng-Ping Hu
Journal:  Biomed Res Int       Date:  2020-02-08       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.